What does the drug do?

Inflammation in the brain and spinal cord is thought to contribute to MND progression. Studies on animals and humans have shown that Interleukin-2 (IL-2) can control a type of immune cell called a Regulatory T Cell (Treg). Tregs play a role in the immune system (fight diseases, infection and help control inflammation) but are dependent on IL-2 for survival and function. At low doses IL-2 has been shown in increase number of Treg cells and function in the blood.

Phase 2 - IMODALS

The Phase 2 trial (IMODALS) enrolled 36 participants into 2 different dosing regimens or placebo over 3 months. The trial showed that the number of circulating Tregs was increased with improved ability to control other immune cell responses that contribute to nerve cell death. This results are promising but the results need to be validated across a longer and larger trial. You can find out more about the trial here.

Phase 2 - MIROCALS

The Phase 2 trial (MIROCALS) will evaluate the efficacy of IL-2 over 18 months in 304 participants. This phase 2 trial looks at a larger cohort of participants over a longer time period compared to IMODALS. The trial has completed recruitment and topline results will be published here as soon as they are available. You can find out more about the trial here.

The trial is fully recruited in the UK and Republic of Ireland.

Latest News

Jan 2022 - Topline results are expected in 2022.

June 2021 - MIROCALS completed recruitment


Want to find out more about IL-2? Check out the resources below:

Blog posts:


Targeting Tregs: IMODALS study paves the way for MIROCALS

Information Sheet:

MIROCALS information sheet


MIROCALS | MND Association

Last updated: 01/08/2022

For further information and support contact our MND Connect helpline

mndconnect 0808 802 6262